Having trouble accessing articles? Reset your cache.

Pimavanserin: Additional Phase III data

Additional data from the double-blind, North American Phase III ACP-103-020 trial in 199 patients with PDP showed that once-daily 40 mg oral pimavanserin met the secondary endpoints of improving CGI-S scores (p<0.001) and CGI-I responder analyses vs. placebo (p=0.002). Specifically, the CGI-I responder analyses showed that about twice as many patients in the pimavanserin

Read the full 544 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers